Paragraph IV filed in 2008 against the 2019 US patents not the 2015 COM patent, so clearly a final approval will only occur after expiration of the 2015 patent. On a side note, Novartis is conducting a long litigation in India where Gleevec was not granted patent protection (total different situation there. For more readings: http://www.economist.com/node/21562226 ), but no suit against Sun Pharma in the US yet.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.